- Prev close
- $404.85
- Day range
- $401.07 – $411.60
- Next earnings
- in 86 days
AMGN slipped -1.6% even as the S&P 500 gained +1.8% and the Nasdaq 100 gained +3.4%, so the move looks stock-specific rather than market-driven. The backdrop is mixed: revenue is growing +9.1% YoY with gross margin +74.0%, but the stock also faces a data-breach headline and a heavy earnings window at 2026-08-04.
AMGN
AMGEN INC
As of Aug 4, 2026
56/100
Worth keeping an eye onHealth ScoreWhy it moved
AMGN fell -1.6% while the S&P 500 gained +1.8% and the Nasdaq 100 gained +3.4%, and its peers were much steadier with ABBV -0.5% and GILD +0.7%. That makes the primary driver stock-specific, not broad market weakness. The clearest stock-specific catalyst in the facts is the report that Amgen is contending with a data breach exposing patient information and proprietary information, which gives the move a company-news explanation rather than a sector-wide one.
Volatility check
This looks more than routine noise because the stock is near its 52-week high at $398 and has a beta of 0.40, so it usually moves less than the market, yet it still fell -1.6% on a day when the broad tape was strong. Fundamentals are intact: revenue is up +9.1% YoY TTM, the latest quarter is up +5.8% YoY, EPS is up +31.3% YoY TTM, and margins are strong at gross +74.0%, operating +28.8%, and net +21.0%. Valuation is not cheap at PE 26.2 and PEG 5.48; a PEG of 5.48 — P/E divided by growth, so investors are paying 5.48x the growth rate — says strong growth is already priced in, which makes the shares more sensitive to bad news. Net: the fundamentals are solid, but the mix of rich valuation and a company-specific breach headline makes the move more than ordinary volatility.
Earnings preview
The next earnings date is 2026-08-04. The facts do not provide published revenue or EPS consensus for this print, so I cannot state a market-expectations number here; the only concrete options signal in the file is a 5.15% implied move for Amgen. The market will be focused on three things: whether the +9.1% revenue growth and +31.3% EPS growth are sustained, whether margins can hold near gross +74.0% and operating +28.8%, and whether management quantifies any financial or operational impact from the data breach.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track AMGN with WhyIHold
Get a plain-English explanation the next time AMGEN INC makes a big move — so you know whether it's benign or worth your attention.